Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.50 |
| ▸ | TACR1 | P25103 | 3/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27682131 | 0.86 | KIF11 (0.47) | KIF11TACR1FFAR1FFAR4BACE1 | |
| SCHEMBL12074184 | 0.84 | ENPP1 (0.45) | KIF11TACR1FFAR1FFAR4BACE1 | |
| SCHEMBL5294357 | 0.84 | TACR1 (0.51) | KIF11TACR1ALDH1A1TSHRCYP1A2 | |
| SCHEMBL5198493 | 0.83 | PDK2 (0.53) | KIF11TACR1FFAR1FFAR4BACE1 | |
| SCHEMBL28961512 | 0.82 | DPP4 (0.48) | ALDH1A1TSHRCYP2C19HTR7DPP4 | |
| SCHEMBL13675366 | 0.81 | KIF11 (0.50) | KIF11TACR1FFAR1FFAR4BACE1 | |
| SCHEMBL5511135 | 0.81 | KIF11 (0.50) | KIF11TACR1FFAR1FFAR4BACE1 | |
| SCHEMBL9295043 | 0.81 | DPP4 (0.62) | KIF11TACR1FFAR1FFAR4BACE1 | |
| SCHEMBL2096005 | 0.81 | KIF11 (0.50) | KIF11TACR1FFAR1FFAR4BACE1 | |
| SCHEMBL17840160 | 0.80 | KIF11 (0.68) | KIF11BACE1ALDH1A1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1122234-A9 | Production methods of alpha, alpha, alpha-trifluoromethylphenyl-substituted benzoic acid and intermediate therefor | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2002-01-16 | — | — | EP | claimed |
| US-20010020110-A1 | Production methods of alpha, alpha, alpha-trifluoromethylphenyl-substituted benzoic acid and intermediate therefor | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2001-09-06 | — | — | US | claimed |
| EP-1122234-A2 | Production methods of alpha, alpha, alpha-trifluoromethylphenyl-substituted benzoic acid and intermediate therefor | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2001-08-08 | — | — | EP | claimed |
| EP-1814861-A1 | SUBSTITUTED 5-OXO PYRAZOLES AND [1,2,4]TRIAZOLES AS ANTIVIRAL AGENTS | SCHERING CORPORATION (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7115749-B2 | Substituted 5-oxo pyrazoles and [1,2,4]triazoles as antiviral agents | SCHERING CORPORATION (US) | 2006-10-03 | — | — | US | disclosed |
| US-20060111412-A1 | For inhibiting hepatitis c virus RNA-dependent polymerase | SCHERING CORPORATION | 2006-05-25 | — | — | US | disclosed |
| WO-2006050035-A1 | SUBSTITUTED 5-OXO PYRAZOLES AND [1,2,4]TRIAZOLES AS ANTIVIRAL AGENTS | SCHERING CORPORATION (US) | 2006-05-11 | — | — | WO | disclosed |
| US-7030120-B2 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | OHKURA NAOTO (JP) | 2004-11-11 | — | — | US | disclosed |
| US-6777414-B1 | INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| EP-1180514-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
| EP-1122234-A9 | Production methods of alpha, alpha, alpha-trifluoromethylphenyl-substituted benzoic acid and intermediate therefor | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2002-01-16 | — | — | EP | disclosed |
| US-20010020110-A1 | Production methods of alpha, alpha, alpha-trifluoromethylphenyl-substituted benzoic acid and intermediate therefor | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2001-09-06 | — | — | US | disclosed |
| EP-1122234-A2 | Production methods of alpha, alpha, alpha-trifluoromethylphenyl-substituted benzoic acid and intermediate therefor | SUMIKA FINE CHEMICALS Co., Ltd. (JP) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111412-A1 | For inhibiting hepatitis c virus RNA-dependent polymerase | RNASE1, POLRMT, POLR2E | KIF11 2080/4885TACR1 2006/4885FFAR1 2844/4885 |
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | APOB, NCEH1, LIPC | KIF11 4800/4885TACR1 1520/4885FFAR1 135/4885 |
| US-20010020110-A1 | Production methods of alpha, alpha, alpha-trifluoromethylphenyl-substituted benzoic acid and intermediate therefor | SLC6A11, CYP4F11, SLC39A11 | KIF11 1001/4885TACR1 1587/4885FFAR1 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.